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PSY47
VARIATION IN PRIMARY CARE CONSULTATION COSTS AMONG 
NON-CANCER PATIENTS TREATED WITH CHRONIC OPIOID 
ANALGESIA IN THE UNITED KINGDOM
Poole CD1, Conway P2, Baxter G2, Currie CJ3
1Pharmatelligence, Cardiff, UK; 2Grunenthal Ltd., Stokenchurch, UK; 3Cardiff University, 
Cardiff, Wales, UK
OBJECTIVES: Chronic pain affects around ﬁ ve million people in the UK. Non-
injectable, strong opioid analgesia is increasingly being used to manage chronic pain 
but this requires careful management to avoid common adverse effects. This study 
aimed to characterise variation in primary care consultation costs as a function of 
analgesic stability among patients treated with long-term, non-injectable opioids. 
METHODS: Cases with at least 6-months’ observation prior to opioid analgesia and 
no history of cancer were extracted from The Health Improvement Network database 
(THIN), a source of anonymised patient-level data from UK general practice. The 
number of different, strong opioid drugs (British Pain Society deﬁ ned) prescribed to 
each patient during their ﬁ rst year of chronic opioid analgesia was used a proxy 
measure of analgesia stability. Primary care consultations were costed using a standard 
tariff at £UK2007. RESULTS: A total of 21,261 cases were studied, of which 54% 
were female and the mean age at initiation of opioid analgesia was 62 years (sd 11). 
Prior to initiating strong opioid analgesia the annual, average, total cost of consulta-
tions with primary care health practitioners was £188 (95%CI £184 to £191). After 
initiation of opioid analgesia, patients treated with a single drug incurred annual 
consultation costs of £546 (£537 to £554) per year on average, and these costs 
increased sharply with each additional opioid: £706 (£686 to £726), £836 (£789 to 
£884), and £975 (£818 to £1132; pANOVA < 0.001) for two, three, and four or more 
opioids, respectively. The majority of consultations (84%) were with general practi-
tioners in the surgery. CONCLUSIONS: The occurrence of persistent pain was associ-
ated with a considerable increase in the rate and the related ﬁ nancial cost of 
consultations with health professionals in primary care. Furthermore, a substantial 
cost gradient was evident among patients who failed to be managed with stable opioid 
monotherapy during their ﬁ rst year of opioid analgesia.
PSY48
RESOURCE USE AND COSTS OF THE GASTRIC BYPASS SURGERY 
VERSUS CLINICAL TREATMENT FOR OBESE PATIENTS WITH 
COMORBIDITIES UNDER THE BRAZILIAN PRIVATE HEALTH CARE 
SYSTEM
Nasciben V
Johnson & Johnson, Sao Paulo, SP, Brazil
OBJECTIVES: To assess use of resources and costs of the surgical versus clinical 
treatment for obese patients with comorbidities, under the Brazilian private health 
care system. METHODS: In order to estimate the differences of resource use and costs 
related to surgery versus clinical treatment one panel of specialists was conducted to 
raise up the resources necessaries for the treatment from pre-operatory evaluation to 
the last medical visit after 5 years. For the clinical treatment group we assumed a 
conservative scenario where the complications are not considered. a micro costing 
technique based on public price lists was applied to value the resources from the panel 
considering only direct medical costs. a discount rate of 5% was assumed. RESULTS: 
For the ﬁ rst year the total costs per patient for the surgically treated group were 
R$14,547, for the open approach and R$31,415 for the laparoscopic approach (pre-
operatory assessment R$2,009, inpatient costs R$2,728 versus R$2,493, procedure 
R$7,233 versus R$24,478, complications R$323 versus R$181 and the clinical follow 
up R$2,254 for both) and for the clinical treated group the total costs per patient was 
R$7,545 where R$5,062 occurred due to the obesity management (diet, consults, and 
drugs for weight management) and R$2,488 for comorbidities (drugs, consults and 
exams for Diabetes TII, hypertension and hypercholesterolemia). After the ﬁ rst year 
the surgically treated group had R$1690 of annually costs for the follow up versus 
R$3290 for the clinical treatment group. After 5 years the total costs were R$22,284 
and R$39,153 for open and laparoscopic surgery and R$19,217 for the clinical treat-
ment. CONCLUSIONS: Findings suggest that gastric bypass can reduce the use of 
resources and costs related to the management of obese patients, under the Brazilian 
private health care system. 
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes 
Studies
PSY49
PATIENTS PREFERENCES IN OVERWEIGHT AND OBESITY THERAPY 
WITH DISCRETE CHOICE EXPERIMENTS
Mühlbacher AC, Bethge S
Hochschule Neubrandenburg, Neubrandenburg, Germany
OBJECTIVES: Overweight is associated with increased risk of morbidity, mortality 
and appears to adversely affect health-related quality of life (HRQOL). Though 
advances in obesity therapy can be observed, the long-lasting outcome is dissatisfying. 
This study aims to investigate patients’ preferences of overweight and obesity therapy 
in the setting of rehabilitation. METHODS: Qualitative and quantitative methods 
were applied to identify key attributes. Literature review, focus groups (N = 44) and 
expert interviews (N = 5) were conducted to elicit relevant attributes and endpoints. 
a total of 64 possible therapy items were surveyed (N = 201) using a classic rating 
scale in 5-point Likert format. Psychometric tests (frequency, factor analysis, reliability 
tests) were used to verify the structure of relevant attributes. Discrete choice experi-
ments were developed using a fractional factorial design in fold over method. For 
statistical data analysis, we used a random effect logit models for the DCE. Finally a 
self-administered survey, measuring preferences, was conducted in Germany in 2009 
(n = 110). RESULTS: A total of 110 patients responded of which 51,82% were male, 
mean age 53,05 years, mean BMI 33,54 kg/m2 (SD 7,73) answered the questionnaire. 
The highest relevance for the respondents’ selection was the aspect of care coordina-
tion (Item 6: Coefﬁ cient 1.473; SE 0.185) and individual therapy (Item 4: Coefﬁ cient 
1.446; SE 0.188). The aspect of infrastructure of care was less relevant in the discrete 
choice experiment. All included attributes lead to signiﬁ cant coefﬁ cients. CONCLU-
SIONS: Weight reduction therapy should enable patients to receive a structured, 
coordinated and predeﬁ ned therapy that is individualized based on personal needs, 
behaviour and circumstances. Patients are willing to abandon infrastructural quality 
for getting better coordination, structure in there therapy. Further research is needed 
to distinguish the possible interpretations of the presented preference dimensions, the 
possibility of including them into weight loss programs and to take notice of hetero-
geneity within patient population in weight loss programs.
PSY50
HEALTH-RELATED QUALITY OF LIFE, HEALTH UTILITIES, AND WORK 
PRODUCTIVITY ASSOCIATED WITH SPECIFIC OBESITY-RELATED 
COMORBIDITIES
Goren A1, Gupta S2, DiBonaventura M1, Freedman D2
1Kantar Health, New York, NY, USA; 2Kantar Health, Princeton, NJ, USA
OBJECTIVES: The study assessed whether, beyond general risks from obesity-related 
comorbidities, speciﬁ c comorbidity types were associated differentially with impair-
ments to health-related quality of life and work productivity. METHODS: Data were 
from the European 2008 National Health and Wellness Survey of German, Spanish, 
Italian, UK, and French adults. Logistic regressions identiﬁ ed signiﬁ cant predictors of 
presence vs. absence of obesity (BMI ≥ 30) among 62 medical conditions, for 52,206 
respondents with valid BMI data (of 53,524 total). Signiﬁ cant predictors were then 
submitted to a principal component analysis (PCA) to identify obesity-related compo-
nents accounting for the most variance. Conditions loading most highly on the result-
ing components were used to predict the following outcomes for all 10,391 obese 
respondents, using multiple regressions: physical (PCS) and mental (MCS) component 
summary scores from the SF-12v2 quality of life instrument, health utilities (SF-6D), 
and percentage overall work impairment (WPAI). Comparisons were against obese 
respondents with none of the PCA-identiﬁ ed conditions, controlling for the other 
conditions. RESULTS: Logistic regressions identiﬁ ed 35 obesity predictors that 
reduced to 9 PCA components with one condition loading prominently on each: 
hypertension, high cholesterol, arthritis, angina, thyroid condition, diabetes, chronic 
bronchitis, psoriasis, and urinary incontinence. All conditions except psoriasis pre-
dicted PCS reductions ranging from 1.22 (with presence of angina) to 9.02 (arthritis), 
ps < 0.001. All except diabetes and angina, and arthritis and hypertension (associated 
with MCS increases), predicted MCS reductions ranging from 0.70 (cholesterol) to 
4.11 (incontinence), ps < 0.05. All except angina predicted health utilities reductions 
ranging from 0.011 (hypertension) to 0.077 (incontinence), ps < 0.001. Among 5,242 
employed respondents, all except angina and psoriasis predicted overall work impair-
ments of 2.11% (hypertension) to 12.48% (bronchitis), ps < 0.05. CONCLUSIONS: 
Obese EU respondents differed signiﬁ cantly in quality of life and productivity impair-
ments, based on both presence and speciﬁ c types of comorbidities. These ﬁ ndings can 
help guide interventions among obesity-related conditions.
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OBJECTIVES: Treating chronic pain involves difﬁ cult trade-offs between the goals of 
pain relief and avoidance of side-effects, but evidence is scarce on relative perspectives 
of physicians and pain sufferers. We studied each group’s preferences concerning 
classical strong opioids in France, Germany, Italy, Spain, Sweden and the UK. 
METHODS: In online, discrete choice experiments (DCE), chronic pain sufferers (n 
= 242) and physicians (n = 270) chose between hypothetical proﬁ les or an opt-out in 
15 choice tasks. Proﬁ le descriptions were based on attributes elicited in focus groups 
with 84 sufferers and semi-structured interviews with 11 physicians. Models were 
speciﬁ ed by multinomial logit and individual respondent part-worths were estimated 
by hierarchical Bayesian regression. RESULTS: All main-effects, but no interactions, 
were signiﬁ cant. Sufferers ranked nausea, pain impact, energy, alertness and constipa-
tion; and physicians ranked pain response, CNS effects, nausea, dosage form and 
constipation in descending order of importance. Sufferers were unwilling to incur 
severe side-effects to relieve pain, opting out in approximately half of the choice tasks, 
while physicians were always willing to trade between proﬁ les. The models predicted 
physicians’ choices well but those of pain sufferers less so. No age, sex or country 
effects were seen but stronger preferences were expressed by the minority (15%) of 
physicians treating non-cancer pain, and by the 55% of sufferers who had ever dis-
continued chronic pain medication and the 41% who reported extreme pain and 
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discomfort in EQ-5D proﬁ le responses. Sufferers’ mean pain scores on an 11-point 
Likert scale were 4.0, 5.7 and 8.6 on their best, average and worst days, respectively. 
CONCLUSIONS: Online DCEs provide a practical means to compare preferences 
between physicians and patients, whose concerns overlap substantially but are 
expressed differently. Sufferers balance pain relief and side-effects. Their refusal to 
trade between undesirable proﬁ les mirrors high reported rates of treatment 
discontinuation.
PSY52
DEVELOPMENT AND CONTENT VALIDATION OF A MULTICENTRIC 
CASTLEMANS DISEASE SYMPTOM SCALE
Teschendorf B1, Vernon M2, O’Quinn S2, van Rhee F3
1Johnson & Johnson, Malvern, PA, USA; 2United BioSource Corporation, Bethesda, MD, 
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OBJECTIVES: Multicentric Castleman’s Disease (MCD) is a rare lymphoproliferative 
disorder characterized by generalized lymphadenopathy and systemic symptoms such 
as fever, night sweats, fatigue, or loss of appetite. While many of these symptoms can 
best be assessed through patient-report there currently is no validated MCD Patient-
Reported Outcome (PRO) instrument available to evaluate symptom severity and 
response to treatment. The purpose of this study was to develop an MCD Symptom 
Scale and assess its content validity through cognitive debrieﬁ ng interviews. 
METHODS: A 16-item MCD PRO was developed through literature review, expert 
clinician input, and qualitative work with 12 patients diagnosed with MCD. Subse-
quent cognitive debrieﬁ ng was used to evaluate the content validity of the PRO with 
additional MCD patients (N = 10) 6 male, 4 female, mean age 44 years. Study pro-
cedures were IRB approved, participants provided written informed consent, inter-
views were conducted using a discussion guide, audio-recordings were transcribed, 
and data were analyzed using qualitative analysis software (Atlas.ti). RESULTS: 
Emergent discussion of symptoms demonstrated that all MCD symptoms experienced 
by patients are evaluated in the PRO. Symptom experience was variable by patient, 
supporting the 24-hour recall period for capturing patient-reported symptom severity. 
All items were consistently understood by participants, who were able to select a 
response using a 5-point response scale to represent their symptom severity experience. 
CONCLUSIONS: The MCD Symptom Scale content was found to be comprehensive. 
Design elements, including response options and recall period were suitable, and 
content validity was conﬁ rmed. The instrument was deemed acceptable for inclusion 
in clinical trials. Psychometric testing is ongoing.
PSY53
ORGANIZATION OF ACUTE PAIN SERVICE (APS) IN THE HUNGARIAN 
HOSPITAL SETTING
Németh F1, Brünner S1, Oláh A2, Pakai A2, Dér A2, Boncz I2, Gerdesics V2, Németh K2
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OBJECTIVES: In our hospital nearly 5000 operations are performed yearly. Based on 
document analysis, the most frequently mentioned complaint was postoperative pain 
in 48 hours following the surgery. There was no Acute Pain Service (APS) in our 
institution, neither existed a standardized professional protocol for executing postop-
erative analgesia. Our aim was to organize APS, wide-spread all over the world but 
hardly known in Hungary. METHODS: Our longitudinal, qualitative examination 
was carried out in May 2008. We investigated the data of patients regarding pain and 
analgesia at ﬁ ve operating departments via not self-ﬁ lled questionnaires and document 
analysis. Patients’ actual pain was measured before and 4th and 24th hours after the 
surgical intervention by visual analogue scale. The analgetics received after surgery 
were documented and compared to application patterns of each department. During 
evaluation T- and Chi-square probes, and variance analysis were used. RESULTS: 
Mean age of the examined sample (n = 130) is 52 years. Mean of the pain scale of 
examined patients is 3,98, higher than the internationally recommended, thus expected 
value of 3. Signiﬁ cant correlation was found (P < 0.05) between operating departments 
and applying frequency of analgetics used, as well as with mean values of the pain 
scale. Most often used medications are: noraminophenazon, tramadol and nalbuphin 
products. There is signiﬁ cant difference between pain values of patients operated at 
departments of surgery and laryngology (p = 0.048), urology and laryngology (p = 
0.036), and surgery and traumatology (p = 0.014). CONCLUSIONS: A perceptual 
form has been developed for regular documentation of pain values measured during 
resting and physical activity, beside the vital parameters, medications exhibited and 
the side-effects. Acute Pain Service (APS) has been introduced in our institution and 
standardized professional protocol has been elaborated for performing postoperative 
analgesia in accordance with preventive approach.
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THE DETERMINANTS OF HRQOL FOR PERSONS TAKING 
PRESCRIPTION PAIN MEDICATIONS: EVIDENCE FOR THE EUROPEAN 
UNION
Langley PC1, Liedgens H2
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OBJECTIVES: This study assesses the quantitative impact of the experience of pain 
on HRQoL for persons taking prescription pain medications in the UK, France, Spain, 
Germany and Italy. METHODS: The study is based on data from the internet based 
2008 National Health and Wellness Survey undertaken in the big 5 EU countries. This 
study identiﬁ ed some 4,503 respondents out of 11,419 who had experienced pain in 
the last month and who had reported taking prescription pain medications. The assess-
ment of the quantitative impact of pain status on HRQoL for the sub-group of pain 
respondents is estimated via three single equation generalized linear (ordinary least 
squares) models which estimate the impact of pain on PCS, MCS and utility scores. 
The model includes a range of variables which have been shown in previous popula-
tion studies to impact HRQoL. These include: socio-demographic factors, health risk 
behaviors, comorbidity status, medication utilization, duration of medication utiliza-
tion and satisfaction with care. The experience of pain is captured by a combination 
of severity and frequency categorical variables. RESULTS: The impact of pain severity 
and frequency on HRQoL for those taking prescription pain medications is substan-
tial. Compared to mild pain experienced less than weekly, the impact of severe daily 
pain is to reduce the PCS score by −14.65 points, the MCS score by −4.60 points and 
utilities by −0.15. Severe pain 4–6 times a week has an impact of −0.11 on utility and 
daily moderate pain −0.08. Overall, the impact of pain is attenuated by reduced sever-
ity and frequency. The impact of pain on HRQoL is substantially greater than the 
impact of comorbidities, duration of medication utilization, socio-demographic and 
health risk factors. CONCLUSIONS: Persons reporting utilizing prescription pain 
medications continue to experience substantial deﬁ cits in the impact of pain severity 
and frequency on HRQoL in the major EU countries.
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QUALITY OF LIFE OF OVERWEIGHT AND OBESE PATIENTS SEEKING 
CARE AT A PHARMACEUTICAL CARE SERVICE IN VENEZUELA
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OBJECTIVES: The purpose of this study was to describe health-related quality of life 
(HRQL) of overweight and obese patients seeking care at the Pharmaceutical Care 
Service of the Proveeduría Farmacéutica IPP-UCV. METHODS: A convenience sample 
of 49 patients, ranging in age from 18 to 83 years was surveyed using a written 
questionnaire from February 2010 to May 2010. HRQL was measured using EuroQol 
comprising the health states descriptive system (EQ-5D) and visual analogue scale 
(EQ-VAS) as a general instrument. RESULTS: The sample consisted of 42 females 
and 7 males. The sample had a mean age of 48.55 years (s.d. 15.25 years). The mean 
weight of patients was 82.88 kg (s.d. 18.24). The mean body mass index (BMI) of 
the patients was 31.99 kg/m2 (s.d 5.77). Thirty-eight patients (77.6%) reported no 
exercising regularly. Thirty-four patients (69.4%) reported some problems with mobil-
ity. Seven patients (14.3%) reported some problems with self-care. Thirty-eight 
patients (77.6%) reported some problems with usual activity. Twenty-ﬁ ve (51%) 
patients reported some problems and 18 (36.7%) reported extreme problems with 
pain. Nineteen subjects (38.8%) reported extreme problems and 17 reported some 
problems with anxiety. CONCLUSIONS: Study limitations include the sample size 
and the use of a convenient patient sample. Overall, this exploratory study demon-
strates that nearly all aspects of HRQL are adversely affected in overweight and obese 
patients seeking care at a pharmaceutical care service in Venezuela.
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SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): UNDERSTANDING THE 
BURDEN
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OBJECTIVES: To assess knowledge of the burden of SLE on patients. METHODS: 
A Medline search was conducted to identify relevant articles published between 2000 
and 2010 in English or non-English language. Search criteria were SLE/lupus plus one 
or more of the following terms: QoL; patient perspective; patient burden of illness/
disease; family impact/burden; prognosis; self; employment/work impact; patient(s) 
and psychological impact; patient(s) and physical impact; psychological impact; 
patient(s) and daily living/functionality; patient(s) and fatigue; impact on social life; 
patients and functioning; compared with rheumatoid arthritis/RA. Prospective studies 
involving ≥100 patients diagnosed with SLE were incorporated into the analysis. To 
focus on the burden of SLE in adult patients, studies in juvenile patients were excluded, 
as were economic analyses, studies relating to the development of HRQoL tools and 
studies of non-pharmacological interventions. RESULTS: The search identiﬁ ed 4244 
articles, 62 of which met the criteria for incorporation into the analysis. Studies 
involved a mean of 460 patients with SLE (range: 100–4,603). SLE was shown to 
affect all aspects of patients’ lives, including physical and mental health, happiness 
and relationships. Common symptoms include fatigue (50–92%), pain (71–89%), 
sleep disturbance (56–88%) and neuropsychiatric symptoms (28–80%), which all 
inﬂ uence HRQoL and work ability. Unemployment is highly prevalent among patients 
with SLE (26–54%) and can impact further on patients’ HRQoL. While most patients 
with SLE (94–100%) report unmet needs primarily reﬂ ecting physical, daily living and 
psychological concerns, physicians appear to place more emphasis on clinical and 
laboratory features. However, clinical measures of disease activity and organ damage 
are poor indicators of HRQoL. Few studies examined the effect of SLE treatment on 
HRQoL. CONCLUSIONS: SLE has a considerable impact on HRQoL and ADL. To 
improve understanding and raise awareness of the burden of SLE, further research is 
needed.
